PPB Pharmacist Pre-registration Exam key terms

The formal approval granted by a national regulatory authority that allows a specific medicinal product to be placed on the market and used for defined indications, with approved labelling, packaging and product information.

The company or legal entity named on the marketing authorisation that is legally responsible for the product, including its quality, safety, efficacy, labelling, advertising and post-market obligations.

The structured set of documents and data submitted to a regulator to support an application, typically organised into administrative, quality, non-clinical and clinical modules with summaries and critical expert reports.

An internationally harmonised format for organising registration applications into five modules, used to make submissions consistent across regions and to reduce duplication of formatting work for applicants.

The approved, regulator-reviewed reference document for a medicine that describes its composition, indications, dosing, contraindications, warnings, interactions, pregnancy data, adverse reactions and pharmacological properties for healthcare professionals.

The approved information sheet supplied inside a medicine's pack, written for patients in clear language, covering what the medicine is, how to take it, possible side effects and storage instructions.

The text and symbols printed on the immediate and outer packaging of a medicine, including name, strength, batch number, expiry date, storage conditions and warnings, which must match the approved content.

A formal change to an already authorised product, such as a new strength, manufacturer, shelf life or indication, classified by its potential impact and assessed by the regulator before implementation.

The regulatory authorisation of a facility to carry out defined activities such as manufacture, import, distribution or retail supply, granted after inspection confirms suitable premises, equipment, personnel and systems.

The set of quality assurance requirements ensuring medicinal products are consistently produced and controlled to quality standards appropriate for their intended use, covering personnel, premises, documentation, production and quality control.

The quality standards governing storage, transport and distribution of medicines through the supply chain, designed to preserve product quality and prevent falsified or unauthorised products from reaching patients.

The professional standard describing the role of pharmacists in meeting patients' medicine-related needs, covering patient assessment, dispensing accuracy, counselling, monitoring, health promotion and professional ethics.

A patient-centred practice model in which the pharmacist takes shared responsibility for medicine outcomes, identifying, resolving and preventing drug-related problems in collaboration with the patient and other prescribers.

Any preventable event that may cause or lead to inappropriate medication use or patient harm, occurring at prescribing, transcribing, dispensing, administration or monitoring stages of the medication use process.

A structured, self-directed cycle of reflecting on practice needs, planning learning, taking part in activities, recording outcomes and evaluating how learning changes professional practice and patient care.

Formal learning activities such as lectures, workshops and accredited courses that update knowledge and skills, typically counted in credits or hours and often recorded as part of a wider professional development portfolio.

The deliberate habit of reviewing one's own actions and decisions, considering what went well, what could improve and what will be done differently, used to convert everyday experience into learning.

A defined set of knowledge, skills and behaviours expected at a given level of professional practice, used to design training, assess performance and plan development for pharmacists and pharmacy support staff.

A pharmacy graduate completing supervised practical training before registration, working under a designated tutor and building a portfolio of evidence against required competencies.

A planned or unannounced on-site examination by an authority to verify compliance with licensing conditions and good practice standards, using observation, interviews, records review and sampling, ending in a written report and findings.

A structured process for investigating the root cause of a detected problem, removing that cause and preventing recurrence, with documented actions, owners, deadlines and effectiveness checks.

Any unplanned departure from an approved procedure, specification or instruction, which must be recorded, assessed for impact on product quality and investigated with appropriate corrective action.

The regulatory approval required before starting a clinical trial in a given country, granted after assessment of the protocol, investigational product data, site suitability and participant protection arrangements.

The documented, voluntary agreement of a competent participant to take part in research after receiving understandable information about purpose, procedures, risks, benefits, alternatives and the right to withdraw at any time.

An independent committee that reviews research protocols and consent documents to protect participants' rights, safety and welfare, and that can approve, require modification of, or reject a study.

The international ethical and scientific quality standard for designing, conducting, recording and reporting trials involving human participants, ensuring credibility of data and protection of trial subjects.

The ongoing regulatory activity of monitoring products on the market through sampling, testing, inspection and reporting, to detect non-compliant, substandard or falsified products and remove them from circulation.

The removal of a medicine from the market or from users because of a defect or safety concern, classified by urgency and executed through traced distribution records with documented retrieval and reconciliation.

A product that either fails to meet quality specifications or has been deliberately misrepresented in identity, composition, source or strength; such products threaten patient safety and undermine trust in health systems.

A harmful and unintended response to a medicine at normal doses, which must be detected, assessed for seriousness and causality, and reported to the authority within defined timelines.

The science and activities relating to detecting, assessing, understanding and preventing adverse effects or any other medicine-related problem, spanning spontaneous reporting, signal review and risk management.

The systematic review of case reports and data sources to identify a new or changed association between a medicine and an adverse event, which then requires evaluation and possible regulatory action.

A periodic submission by the marketing authorisation holder summarising worldwide safety data, exposure, case analyses and benefit-risk conclusions for a product over a defined reporting interval.

An untoward medical occurrence that results in death, is life-threatening, requires hospitalisation or prolongs it, causes persistent disability, or is a congenital anomaly, requiring expedited reporting.

The testing and sampling activities performed against specifications to confirm identity, strength, purity and other quality attributes of materials and finished products before release.

The formal decision by an authorised person that a batch meets its specifications and may be released for sale or supply, based on review of manufacturing and testing records and compliance with GMP.

A test result that falls outside established acceptance criteria, triggering a documented laboratory investigation to determine whether the cause is laboratory error, manufacturing fault or a valid result before any decision on the batch.

A web-based platform used to submit applications, licence renewals, adverse event reports or inspection responses electronically, providing audit trails, status tracking and structured data capture for the authority.